Report
Nyxoah - Q3 23 results
Yesterday evening, Nyxoah published its Q3 23 results and held a conference call. Overall, no major surprises. Management indicates that Q3 is always seasonally weak due to the holiday period. We should see an increase in revenues in Q4. Although revenue ramp-up appears to be slower than what we initially envisioned in Europe, we are not too worried, especially as the US market opportunity represents the biggest value driver for Nyxoah. Operating-wise, Nyxoah is still on track to report the top-line readouts from its US pivotal DREAM trial around March 2024. Modular PMA submission is progressing well with the third
Underlying
Nyxoah
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.